Home / Business and Economy / Lilly Surges on Blockbuster Drug Demand
Lilly Surges on Blockbuster Drug Demand
4 Feb
Summary
- Eli Lilly's 2026 revenue guidance exceeded analyst expectations.
- Demand for Zepbound and Mounjaro significantly boosted earnings.
- Drug pricing agreements for Medicare beneficiaries are in place.
Eli Lilly has reported fourth-quarter earnings and issued 2026 revenue guidance that significantly exceeded analyst forecasts. This strong performance is largely driven by exceptional demand for its highly successful Zepbound weight loss drug and Mounjaro diabetes treatment. The company anticipates its 2026 revenue will range between $80 billion and $83 billion, surpassing the $77.62 billion expected by LSEG analysts.
Lilly's adjusted earnings per share are projected to be between $33.50 and $35 for 2026, also topping the $33.23 estimate. These positive results stand in contrast to rival Novo Nordisk's recent warning of declining sales and profits due to U.S. price reductions and patent expirations in key international markets. Lilly is actively working to solidify its leading position in the lucrative GLP-1 drug market, especially with Novo Nordisk's successful launch of its own obesity pill.
